<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03531606</url>
  </required_header>
  <id_info>
    <org_study_id>KY_Mpro3</org_study_id>
    <nct_id>NCT03531606</nct_id>
  </id_info>
  <brief_title>The Effects of Mechnikov Probiotics on Symptom and Surgical Outcome</brief_title>
  <official_title>The Effects of Mechnikov Probiotics on Symptom and Surgical Outcome After Anterior Resection of Colon Cancer; Double-blind, Randomized, Placebo-controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kye Bong-Hyeon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Catholic University of Korea</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this clinical trial study was to evaluate the prevalence of colon cancer among
      the symptom (s) of anterior resection syndrome that may occur after surgery in patients for
      efficacy and safety in Metchnik probiotic ingestion.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of the clinical trial is to evaluate the efficacy and safety of the syndrome that
      may occur after colon cancer surgery, To evaluate the efficacy and safety of the improvement
      effect of the defecatory activity on the improvement of the Medienkov probiotics biotics on
      the patients who have the deficit function and planned to surgery.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 12, 2016</start_date>
  <completion_date type="Anticipated">June 30, 2018</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This study has been designed for randomized, double Blinded, placebo clinical trial.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Anterior resection syndrome improvement change</measure>
    <time_frame>1 week before surgery, 4 weeks after surgery, 5 weeks after surgery</time_frame>
    <description>3 times performed through questionnaire</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bowel examination</measure>
    <time_frame>4 weeks after surgery, 5 weeks after surgery</time_frame>
    <description>2 times performed through questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life of Cancer Patients(EORTC QLQ-C30)</measure>
    <time_frame>1 week before surgery, 4 weeks after surgery</time_frame>
    <description>2 times performed through questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Markers related Inflammation</measure>
    <time_frame>1 week before surgery, 4 weeks after surgery</time_frame>
    <description>WBC, Neutrophil, lymphocyce, monocyte, Plt count, neutrophil-lymphocyte ratio</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NSI(Nutritional Screening Index)</measure>
    <time_frame>1 week before surgery, 1.5 weeks after surgery, 4 weeks after surgery</time_frame>
    <description>PG-SGA: Patient-Generated Subjective Global Assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clavien-Dindo Classification</measure>
    <time_frame>1 week after surgery, 1.5 weeks after surgery, 4 weeks after surgery</time_frame>
    <description>Assessment through &quot;Clavien-Dindo Classification&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NGS, SCFA</measure>
    <time_frame>1 week before surgery, 1 week after surgery, 4 weeks after surgery, 5 weeks after surgery</time_frame>
    <description>NGS(New Generation Sequencing), SCFA(Short-Chain Fatty Acid)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Other biomarkers</measure>
    <time_frame>1 week before surgery, 4 weeks after surgery</time_frame>
    <description>Zonulin, other Cytokines</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">68</enrollment>
  <condition>Sigmoid Colon Cancer</condition>
  <arm_group>
    <arm_group_label>Experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Using placebo comparator with experimental one, it will be compared between two group for comparison of placebo comparator with experimental one.
The patients enrolled into expeimental group will take one pack of 'Mechnicov probiotics' twice a day for 4 weeks from 1 week before surgery.
(1 week before surgery and 3 weeks after surgery)
The patients in placebo and experimental group should take a part in this clinical trial under the condition of 'anterior resection of colon cancer'</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo comparator</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Using placebo comparator with experimental one, it will be compared between two group for comparison of placebo comparator with experimental one.
The patients enrolled into placebo comparator group will take one pack of 'Placebo' which is composed of lactose and simulates a 'Mechnicov probiotics' twice a day for 4 weeks from 1 week before surgery.
(1 week before surgery and 3 weeks after surgery)
The patients in placebo and experimental group should take a part in this clinical trial under the condition of 'anterior resection of colon cancer'</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mechnicov probiotics</intervention_name>
    <description>Using placebo comparator with experimental one, it will be compared between two group for comparison of placebo comparator with experimental one.
The patients enrolled into expeimental group will take one pack of 'Mechnicov probiotics' twice a day for 4 weeks from 1 week before surgery.
(1 week before surgery and 3 weeks after surgery)
The patients in placebo and experimental group should take a part in this clinical trial under the condition of 'anterior resection of colon cancer'</description>
    <arm_group_label>Experimental</arm_group_label>
    <other_name>Anterior resection</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Using placebo comparator with experimental one, it will be compared between two group for comparison of placebo comparator with experimental one.
The patients enrolled into expeimental group will take one pack of 'Mechnicov probiotics' twice a day for 4 weeks from 1 week before surgery.
(1 week before surgery and 3 weeks after surgery)
The patients in placebo and experimental group should take a part in this clinical trial under the condition of 'anterior resection of colon cancer'</description>
    <arm_group_label>Placebo comparator</arm_group_label>
    <other_name>Anterior resection</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Adult male or female aged 20 to over 75 years old

          2. As histologically and radiologically diagnosed S colon cancer, those who is scheduled
             for anterior resection

          3. Those who have been agreed to participate in this trial (through Informed consent)
             before initiation of clinical trial.

        Exclusion Criteria:

          1. Those who have metastatic colorectal cancer screening

          2. Those who have urinary incontinence or fecal incontinence

          3. Those who received preoperative chemotherapy or radiotherapy

          4. Those who have a history of severe cerebral vascular disease (cerebral infarction,
             cerebral hemorrhage, etc.), severe cardiac disease (unstable angina pectoris,
             myocardial infarction, arrhythmia requiring heart failure heart failure therapy)

          5. Those who have neurologist or psychologically important psychiatric history or current
             disease

          6. Those who have alcohol addiction, substance abuse

          7. Those who have Immune system, infectious infectious disease, gastrointestinal tract
             disease patients (inflammatory bowel disease)

          8. Those who have uncontrolled hypertension, diabetes patients

          9. Those who have creatinine with more than twice from normal upper limit in site

         10. Those who have AST(GOT) or ALT(GPT) with more than three times from normal upper limit
             in site

         11. Those who have probiotics, antibiotics, continually within the last one week

         12. Those who is pregnant women, breastfeeding women and have pregnancy plans or do not
             agree to appropriate contraception methods choice

         13. Those who have been participated within three months or have plans to participate in
             another clinical trial after the start of this clinical trial

         14. under the investigator's judgment, those who is not qualified to participate this
             clinical trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>SungSik Jang, Ph.D</last_name>
    <role>Study Director</role>
    <affiliation>R &amp;D</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>JuHyun Kim, Ph.D</last_name>
    <phone>+82-010-4822-1194</phone>
    <email>monera@re.yakult.co.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>In Kyu Lee</name>
      <address>
        <city>Seoul</city>
        <zip>06591</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bong-Hyeon Kye, MD</last_name>
      <email>ggbong@catholic.ac.kr</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 15, 2018</study_first_submitted>
  <study_first_submitted_qc>May 8, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 22, 2018</study_first_posted>
  <last_update_submitted>May 21, 2018</last_update_submitted>
  <last_update_submitted_qc>May 21, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>The Catholic University of Korea</investigator_affiliation>
    <investigator_full_name>Kye Bong-Hyeon</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colonic Neoplasms</mesh_term>
    <mesh_term>Sigmoid Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

